Exelixis Inc. will report initial data from an important cancer trial in the fourth quarter, the company said Wednesday.
The South San Francisco drug developer said it hit a pre-set number of “events” in its Phase III trial of its drug, cabozantinib, in patients with medullary thyroid cancer.
No comments:
Post a Comment